[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352921-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-352921-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","bi-905711-a-trailr2cdh17-bispecific-antibody-alone-or-with-chemotherapy-for-patients-with-advanced-gastrointestinal-cancers-phase-i-study-findings","BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers - Phase I Study Findings","","BI 905711, a TRAILR2/cadherin-17 (CDH17) bispecific antibody, was evaluated based on preclinical evidence of apoptotic pathway activation and antitumor activity. Two phase Ia/Ib studies assessed BI 905711 monotherapy or combination therapy in advanced, refractory gastrointestinal cancers, determining MTD and RP2D/RDE. Phase Ia measured safety, efficacy, and pharmacokinetics/pharmacodynamics; phase Ib confirmed selected dosing and regimens.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bi-905711-a-trailr2cdh17-bispecific-antibody-alone-or-with-chemotherapy-for-patients-with-advanced-gastrointestinal-cancers-phase-i-study-findings/352921/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bi-905711-a-trailr2cdh17-bispecific-antibody-alone-or-with-chemotherapy-for-patients-with-advanced-gastrointestinal-cancers-phase-i-study-findings/352921.png","ImageObject",300,407,{"name":42,"@type":43},"Nguyễn Văn Học","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary goal of the phase I studies for BI 905711?","Question",{"text":63,"@type":64},"To determine the maximum tolerated dose (MTD) in phase Ia and establish the recommended phase II dose (RP2D)/recommended dose for expansion (RDE) in phase Ib, alongside safety and pharmacokinetic/pharmacodynamic evaluation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment approaches were tested?",{"text":68,"@type":64},"BI 905711 monotherapy was tested in one study, while another study evaluated BI 905711 combined with chemotherapy (FOLFIRI) plus bevacizumab in patients with advanced gastrointestinal cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What did safety and toxicity results show?",{"text":72,"@type":64},"No dose-limiting toxicities (DLT) occurred in the monotherapy cohort, and hepatotoxicity was limited overall. In the combination cohort, two patients reported DLTs, and most patients experienced treatment-related adverse events (TRAE).",{"name":74,"@type":61,"acceptedAnswer":75},"How was target engagement and antitumor activity characterized?",{"text":76,"@type":64},"Pharmacokinetic/pharmacodynamic data showed linear dose exposure and at least two-fold activation of plasma caspase 3/7, while clinical activity was described as limited with stable disease observed in both cohorts.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},352921,1790200066,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":26,"preview_urls":151},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0638](https://doi.org/10.1158/2767-9764.CRC-25-0638)  OPEN ACCESS  \nBI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings  \nJames J. Harding1,2, Ralf Hofheinz3, Elena ´Elez4, Yasutoshi Kuboki5, Drew W. Rasco6, Michael Cecchini7, Lin Shen8, Min He9, Shorena Archuadze10, Niraj Chhaya9, Franziska Haderk10, Lisa Mszros10, Stefan Wlke10, Tetsuya Katakabe11, Robert M. Lorence9, Eric Van Cutsem12, Scott Kopetz13, and Shubham Pant13  \n􀀶  \nABSTRACT  \nPurpose: BI 905711, a TRAILR2/cadherin-17 (CDH17) bispecific antibody, demonstrated preclinical apoptotic pathway activation and antitumor activity. Two phase Ia/Ib studies tested BI 905711 monotherapy (NCT04137289) or combination therapy (NCT05087992) in advanced, refractory gastrointestinal (GI) cancers.  \nPatients and Methods: Both studies aimed to determine the maximum tolerated dose (MTD; phase Ia) and recommended phase II dose (RP2D)/recommended dose for expansion (RDE; phase Ib). In phase Ia, patients received BI 905711 monotherapy (0.02–4.8 mg/kg) or 0.6 to 1.2 mg/kg plus biweekly folinic acid (leucovorin), 5-fluorouracil, and irinotecan (FOLFIRI) and bevacizumab. Phase Ib assessed selected doses and regimens given biweekly or weekly (3 weeks on and 1 week off) . Safety, efficacy, and pharmacokinetics/pharmacodynamics were evaluated.  \nResults: In NCT04137289, 110 patients [median age 61 years; 80% with colorectal cancer; median of three prior therapies (range, 1–6)] received monotherapy. No dose-limiting toxicities (DLT) occurred, MTD was not reached, RP2D was not determined, and 48. 2% of patients had treatment-related adverse events (TRAE), most commonly nausea (16.4%) . In 104 response-evaluable patients, 22.1% achieved stable disease (SD) . In NCT05087992, 12 patients with  \ncolorectal cancer (median age 54.5 years) received combination treatment. Two patients reported DLTs, MTD was not reached, and the selected RDE was 0.6 mg/kg plus biweekly FOLFIRI and bevacizumab. Most patients (91.7%) had TRAEs, including decreased appetite (33.3%), alanine transaminase increased, aspartate transaminase increased, and diarrhea (25% each) . Eleven patients (91.7%) achieved SD. Pharmacokinetic/pharmacodynamic data indicated linear dose exposure and ≥2-fold activation of plasma caspase 3/7 .  \nConclusions: In heavily pretreated patients with GI tumors, BI 905711 monotherapy or with FOLFIRI plus bevacizumab displayed a manageable safety profile and limited clinical activity.  \nSignificance: Translating preclinical activity of TRAILR2 agonists into the clinic has been hampered by severe hepatotoxicity. BI 905711, abispecific antibody against TRAILR2 and CDH17, was developed to enhance efficacy and reduce hepatotoxicity. Two phase 1 studies (NCT04137289 and NCT05087992) demonstrated tolerability and minimal hepatotoxicity, dose-proportional pharmacokinetics, and increased markers of target engagement. Antitumor activity was limited. These data show that BI 905711 has reduced TRAIL-related hepatotoxicity in the clinic.  \n1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2Weill Cornell Medical College, New York, New York. 3Universittsklinikum Mannheim, Mannheim, Germany. 4Vall d’Hebron University Hospital, Barcelona, Spain. 5National Cancer Center Hospital East, Kashiwa, Japan. 6The START Center for Cancer Research, San Antonio, Texas. 7Yale Cancer Center, Yale University, New Haven, Connecticut. 8Peking University Cancer Hospital and Institute, Beijing, China. 9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut. 10Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany. 11Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan. 12University Hospitals Gasthuisberg, University of Leuven (KUL), Leuven, Belgium. 13University of Texas MD Anderson Cancer Center, Houston, Texas.  \nCli","cbCaihiKtW0DddbW","https://ap.wps.com/l/cbCaihiKtW0DddbW","pdf",2674086,13,"English","# ABSTRACT\n## Purpose\n## Patients and Methods\n## Results\n## Conclusions\n## Significance\n# Introduction\n## Background on gastrointestinal cancers\n## Apoptosis and TRAIL signaling","[{\"question\":\"What was the primary goal of the phase I studies for BI 905711?\",\"answer\":\"To determine the maximum tolerated dose (MTD) in phase Ia and establish the recommended phase II dose (RP2D)/recommended dose for expansion (RDE) in phase Ib, alongside safety and pharmacokinetic/pharmacodynamic evaluation.\"},{\"question\":\"What treatment approaches were tested?\",\"answer\":\"BI 905711 monotherapy was tested in one study, while another study evaluated BI 905711 combined with chemotherapy (FOLFIRI) plus bevacizumab in patients with advanced gastrointestinal cancers.\"},{\"question\":\"What did safety and toxicity results show?\",\"answer\":\"No dose-limiting toxicities (DLT) occurred in the monotherapy cohort, and hepatotoxicity was limited overall. In the combination cohort, two patients reported DLTs, and most patients experienced treatment-related adverse events (TRAE).\"},{\"question\":\"How was target engagement and antitumor activity characterized?\",\"answer\":\"Pharmacokinetic/pharmacodynamic data showed linear dose exposure and at least two-fold activation of plasma caspase 3/7, while clinical activity was described as limited with stable disease observed in both cohorts.\"}]","BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers - Phase I Study Findings | PDF",1790101991,33,[152,156],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/be19bcc4fb482e2113c85c9e74b5ddde.webp",983,1263,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/b38544c4775f101f7760b0513ac08468.webp",982,1262]